Here’s what transpired at the annual AASLD The Liver Meeting® 2025 (Washington DC) for Day #4, 11/10/2025 —
Programming highlights
- Morning sessions included the State-of-the-Art Lecture, major general hepatology updates, and “Meet the Experts” (MTE) format sessions.
- Poster sessions ran throughout the day in Hall DE, covering broad topics including MASLD/MASH, fibrosis, gut-liver axis/microbiome, cellular/molecular biology.
- Global programming featured a session on Global Perspectives on Hepatitis B Management in Pregnancy (in partnership with Indian National Association for the Study of Liver/INASL) on Monday.
- The Exhibit Hall was open (9:30 AM – 5:00 PM) allowing for networking, industry symposia and vendor engagement.
Morning & midday scientific sessions
- Liver Cell Biology SIG Poster Highlights — 7:45–8:15 AM, Science in the Park – Site A (L3).
Titles included: “Lipid-Immune Crosstalk in HCC…”, “HIF signaling in endothelial cells…”, and “Nuclear lipid droplets in liver diseases.” Speakers: Yasmeen Attia, PhD; Chang Kyung (Joanna) Kim, MD/PhD; Norihiro Imai, MD, PhD; Moderators: Kari Nejak-Bowen, PhD; Wen-Xing Ding, MD, PhD. - Global Perspectives on Hepatitis B Management in Pregnancy (AASLD–INASL Community Conversation) — 9:45–10:45 AM, Room 146B. Useful for multi-etiology risk-stratification and perinatal pathways.
Poster sessions
- Cellular & Molecular / MASLD-related mechanisms
• Poster #4246 – Sensing of phosphatidic acid by mTORC1 in liver and development of MASLD. (Cellular & Molecular Biology; 8:00 AM–5:00 PM, Hall DE). - Biomarkers & risk prediction
• Poster #4323 – Higher plasma kynurenine:tryptophan ratio predicts incident hepatic fibrosis in women with HIV. (Gut–Liver Axis & Microbiome; 8:00 AM–5:00 PM, Hall DE). - Transplant / health services
• Poster #3054 – Factors associated with being “too early” for liver transplantation (California Liver Network) (Health Services/Public Health Research; 8:00 AM–5:00 PM, Hall DE).
• Poster #3064 – Short- and long-term patient-reported symptoms after COVID-19 exposure in cirrhosis. (Health Services/Public Health Research; 8:00 AM–5:00 PM, Hall DE).
• Poster #3185 – Geranylgeranyl pyrophosphate regulates human hepatic stellate cell function… (Hepatobiliary Neoplasia; 8:00 AM–5:00 PM, Hall DE).
Late-breaking clinical session
- Late-Breaking Abstract Parallel Session 2 — 5:00–6:30 PM, Hall A (General Session). Objectives note recent clinical trials in MASH, hepatitis, and PBC—useful for therapy and biomarker landscape updates. AASLD